RespireRx Pharmaceuticals Inc. (OTCMKTS:RSPI) Short Interest Down 81.5% in March

RespireRx Pharmaceuticals Inc. (OTCMKTS:RSPIGet Rating) was the target of a significant drop in short interest in the month of March. As of March 31st, there was short interest totalling 500 shares, a drop of 81.5% from the March 15th total of 2,700 shares. Based on an average daily trading volume, of 718,500 shares, the short-interest ratio is currently 0.0 days.

Shares of OTCMKTS RSPI remained flat at $$0.01 during mid-day trading on Wednesday. 82,540 shares of the company traded hands, compared to its average volume of 186,868. The firm’s 50 day moving average price is $0.01 and its 200-day moving average price is $0.02. RespireRx Pharmaceuticals has a twelve month low of $0.01 and a twelve month high of $0.05.

RespireRx Pharmaceuticals Company Profile (Get Rating)

RespireRx Pharmaceuticals Inc engages in the discovery, development, and commercialization of pharmaceuticals for the treatment of neurological and psychiatric disorders. It has two drug platforms comprising ResolutionRx, a pharmaceutical cannabinoids platform, which includes dronabinol that acts upon the nervous system's endogenous cannabinoid receptors for use in refractory chemotherapy-induced nausea and vomiting, as well as for anorexia in patients with AIDS; and EndeavourRx, a neuromodulators platform that comprises AMPAkines program, including proprietary compounds that are positive allosteric modulators (PAMs) of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-type glutamate receptors to promote neuronal function, and GABAkines program, including proprietary compounds that are PAMs of GABAA receptors.

Featured Stories

Receive News & Ratings for RespireRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RespireRx Pharmaceuticals and related companies with's FREE daily email newsletter.